In recent years, immunotherapy was approved as first‐line therapy either as monotherapy for NSCLC patients with PD‐L1 expression ≥50% or in combination with different chemotherapy backbones independent of PD‐L1 expression based on pivotal phase 3 trials Keynote‐024, Keynote‐189, Keynote‐407, IMpower150, IMpower133. This evidence concerns the gene CD274 and non-small cell lung carcinoma.